Market Overview

Biogen Q3 Earnings Outlook


On Tuesday, Biogen (NASDAQ: BIIB) will release its latest earnings report. Benzinga's outlook for Biogen is included in the following report.

Earnings and Revenue

Analysts covering Biogen modeled for quarterly EPS of $6.80 on revenue of $3.33 billion.

Biogen EPS in the same period a year ago totaled $6.31. Sales were $3.08 billion. If the company were to match the consensus estimate when it reports Tuesday, EPS would be up 7.77 percent. Revenue would be up 8.19 percent from the same quarter last year. Here's how the Biogen's reported EPS has stacked up against analyst estimates in the past:


Quarter Q2 2018 Q1 2018 Q4 2017 Q3 2017
EPS Estimate 5.26 5.92 5.47 5.67
EPS Actual 5.8 6.05 5.26 6.31

Stock Performance

Over the last 52-week period, shares are down 7.01 percent. Given that these returns are generally negative, long-term shareholders are probably down going into this earnings release. Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. The average rating by analysts on Biogen stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

Biogen's Q3 conference call is scheduled to begin at 8:00 a.m. ET and can be accessed here:

Posted-In: Earnings News


Related Articles (BIIB)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Alkermes Q3 Earnings Preview

Mid-Afternoon Market Update: JetPay Climbs On Acquisition News; Opus Bank Shares Slide